% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cao:135951,
      author       = {X. Cao$^*$ and Q. Tang$^*$ and T. Holland-Letz$^*$ and M.
                      Gündert$^*$ and K. Cuk$^*$ and S. Schott and J. Heil and M.
                      Golatta and C. Sohn and A. Schneeweiss and B. Burwinkel$^*$},
      title        = {{E}valuation of {P}romoter {M}ethylation of {RASSF}1{A} and
                      {ATM} in {P}eripheral {B}lood of {B}reast {C}ancer
                      {P}atients and {H}ealthy {C}ontrol {I}ndividuals.},
      journal      = {International journal of molecular sciences},
      volume       = {19},
      number       = {3},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2018-00688},
      pages        = {900 -},
      year         = {2018},
      abstract     = {Breast cancer (BC) is the most common cancer among women
                      and has high mortality rates. Early detection is supposed to
                      be critical for the patient's prognosis. In recent years,
                      several studies have investigated global DNA methylation
                      profiles and gene-specific DNA methylation in blood-based
                      DNA to develop putative screening markers for cancer.
                      However, most of the studies have not yet been validated. In
                      our study, we analyzed the promoter methylation of RASSF1A
                      and ATM in peripheral blood DNA of 229 sporadic patients and
                      151 healthy controls by the MassARRAY EpiTYPER assay. There
                      were no significant differences in DNA methylation levels of
                      RASSF1A and ATM between the sporadic BC cases and the
                      healthy controls. Furthermore, we performed the Infinium
                      HumanMethylation450 BeadChip (450K) array analysis using 48
                      sporadic BC cases and 48 healthy controls (cases and
                      controls are the same from those of the MassARRAY EpiTYPER
                      assay) and made a comparison with the published data. No
                      significant differences were presented in DNA methylation
                      levels of RASSF1A and ATM between the sporadic BC cases and
                      the healthy controls. So far, the evidence for powerful
                      blood-based methylation markers is still limited and the
                      identified markers need to be further validated.},
      cin          = {C080 / C060},
      ddc          = {570},
      cid          = {I:(DE-He78)C080-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29562656},
      pmc          = {pmc:PMC5877761},
      doi          = {10.3390/ijms19030900},
      url          = {https://inrepo02.dkfz.de/record/135951},
}